Efficacy and safety of once‐weekly semaglutide 2.4 mg for weight management in participants from China: A prespecified analysis of the STEP 7 randomized clinical trial

Documents similaires

• Impact of baseline characteristics on the efficacy of once‐weekly subcutaneous semaglutide among participants with type 2 diabetes : A post hoc analysis of SUSTAIN China
  par: Linong Ji, et autres
  Publié: (2024)
• Efficacy and safety of once‐weekly subcutaneous semaglutide 2.4 mg for the management of overweight or obesity in Asian populations: A systematic review, meta‐analysis and meta‐regression of randomised trials
  par: Hendra Zufry, et autres
  Publié: (2025)
• Effect of semaglutide 2.4 mg on physical functioning and weight‐ and health‐related quality of life in adults with overweight or obesity: Patient‐reported outcomes from the STEP 1–4 trials
  par: Domenica Rubino, et autres
  Publié: (2024)
• Treatment effect of semaglutide 2.4 mg on health‐related quality of life from STEP 1 SF‐6D derived from SF ‐36 with Australian weights
  par: Pavol Kral, et autres
  Publié: (2024)
• Efficacy and safety of once‐weekly insulin icodec in type 2 diabetes: A meta‐analysis of ONWARDS phase 3 randomized controlled trials
  par: Sahana Shetty, et autres
  Publié: (2024)